US · ALNY · BIOTECHNOLOGY
Alnylam Pharmaceuticals, Inc. (ALNY) intrinsic value and stock valuation
$143.82as of 2026-11-21 · Mkt cap 30.6B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Alnylam Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values ALNY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ALNY’s statements →
Alnylam Pharmaceuticals, Inc. Graham Number
Graham Number: $18.02d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Regeneron Pharmaceuticals, Inc. (REGN) $920.69
- Cigna Corporation (CI) $270.90
- Cencora, Inc. (COR) $339.09
- Cardinal Health, Inc. (CAH) $272.81
- argenx SE (ARGX) $925.70
- Edwards Lifesciences Corporation (EW) $101.85
- Becton, Dickinson and Company (BDX) $212.78
- IDEXX Laboratories, Inc. (IDXX) $676.21
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M |
| Operating income | $501.6M | -$-176.88M | -$-282.18M | -$-785.07M | -$-708.65M |
| Net income | $313.8M | -$-278.16M | -$-440.24M | -$-1.13B | -$-852.82M |
| EPSd | $2.33M | -$-2.18M | -$-3.52M | -$-9.3M | -$-7.2M |
| Operating cash flow | $524.1M | -$-8.31M | $104.2M | -$-541.27M | -$-641.69M |
| Capital expenditure | -$-58.7M | -$-34.28M | -$-62.21M | -$-72.06M | -$-76.37M |
| Free cash flow | $465.4M | -$-42.59M | $42M | -$-613.33M | -$-718.07M |
| Total assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B |
| Total debt | $1.28B | $1.3B | $1.31B | $1.32B | $997.6M |
| Net debt | -$-378.86M | $329.6M | $492.7M | $453.9M | $177.6M |
| Total equity | $789.2M | $67.1M | -$-220.64M | -$-158.22M | $588.2M |
| Cash and short-term investments | $2.91B | $2.69B | $2.44B | $2.19B | $2.44B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M |
| Cost of revenue | $677.2M | $323.4M | $310.4M | $168.8M | $140.1M |
| Gross profit | $3.04B | $1.92B | $1.52B | $868.6M | $704.1M |
| Research and development expenses | $1.32B | $1.13B | $1B | $883M | $792.2M |
| Selling, general and administrative expenses | $1.21B | $975.5M | $795.7M | $770.7M | $620.6M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | -$-2.05M |
| Operating expenses | $2.54B | $2.1B | $1.8B | $1.65B | $1.41B |
| Cost and expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B |
| Interest income | $111.5M | $122M | $95.6M | $24.8M | $1.58M |
| Interest expense | $252.6M | $141.9M | $121.2M | $156M | $143M |
| Depreciation and amortization | $55.7M | $56.7M | $54.1M | $44.5M | $47.6M |
| Ebitda | $631.4M | -$-178.85M | -$-258.24M | -$-926.56M | -$-661.56M |
| Operating income | $501.6M | -$-176.88M | -$-282.18M | -$-785.07M | -$-708.65M |
| Total other income/expenses, net | -$-178.43M | -$-200.49M | -$-151.34M | -$-341.92M | -$-143.49M |
| Income before tax | $323.2M | -$-377.38M | -$-433.52M | -$-1.13B | -$-852.14M |
| Income tax expense | $9.4M | -$-99.22M | $6.72M | $4.16M | $680K |
| Net income | $313.8M | -$-278.16M | -$-440.24M | -$-1.13B | -$-852.82M |
| Weighted average shares outstanding | $131M | $127.7M | $124.9M | $121.7M | $118.5M |
| Weighted average diluted shares outstanding | $134.7M | $127.7M | $124.9M | $121.7M | $118.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.91B | $2.69B | $2.44B | $2.19B | $2.44B |
| Net receivables | $777.6M | $405.3M | $327.8M | $238M | $198.6M |
| Inventory | $82.7M | $78.5M | $89.2M | $129M | $86.4M |
| Total current assets | $4.05B | $3.3B | $2.98B | $2.69B | $2.81B |
| Property, plant and equipment, net | $708.1M | $693.9M | $725.8M | $738.6M | $733.6M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $915.7M | $944.7M | $847.2M | $854.1M | $834.7M |
| Total assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B |
| Accounts payable | $115.7M | $88.4M | $55.5M | $98.1M | $73.4M |
| Short-term debt | $45.5M | $41.9M | $41.5M | $42M | $40.6M |
| Deferred revenue | $4.84M | $55.5M | $102.8M | $42.1M | $149.5M |
| Total current liabilities | $1.47B | $1.19B | $967.8M | $767.9M | $695.7M |
| Long-term debt | $1.23B | $1.25B | $1.26B | $1.28B | $957M |
| Deferred revenue, non-current | $0.00 | $0.00 | $188.2M | $193.8M | $152.4M |
| Total non-current liabilities | $2.71B | $2.99B | $3.08B | $2.94B | $2.36B |
| Capital lease obligations | $270.6M | $271.4M | $284.6M | $303.3M | $321.9M |
| Total liabilities | $4.18B | $4.17B | $4.05B | $3.7B | $3.06B |
| Common stock | $1.32M | $1.29M | $1.26M | $1.24M | $1.2M |
| Retained earnings | -$-6.7B | -$-7.29B | -$-7.01B | -$-6.57B | -$-5.44B |
| Accumulated other comprehensive income (loss) | -$-20.1M | -$-34.52M | -$-23.38M | -$-44.65M | -$-33.26M |
| Total equity | $789.2M | $67.1M | -$-220.64M | -$-158.22M | $588.2M |
| Total investments | $1.25B | $1.73B | $1.63B | $1.33B | $1.62B |
| Total debt | $1.28B | $1.3B | $1.31B | $1.32B | $997.6M |
| Net debt | -$-378.86M | $329.6M | $492.7M | $453.9M | $177.6M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $313.8M | -$-278.16M | -$-440.24M | -$-1.13B | -$-852.82M |
| Depreciation and amortization | $55.7M | $56.7M | $97M | $85.6M | $89.7M |
| Stock-based compensation | $348.2M | $272.1M | $221.7M | $230.7M | $165.7M |
| Change in working capital | -$-444.78M | -$-214.08M | $10.8M | -$-35.55M | -$-162.82M |
| Accounts receivable | -$-359.96M | -$-86.55M | -$-87.94M | -$-45.6M | -$-101.8M |
| Inventory | $8.47M | $13.6M | $18.4M | -$-34.14M | -$-26.41M |
| Accounts payable | $75.1M | $91.1M | $80.8M | $191.8M | $88.2M |
| Net cash provided by operating activities | $524.1M | -$-8.31M | $104.2M | -$-541.27M | -$-641.69M |
| Investments in property, plant and equipment | -$-58.7M | -$-34.28M | -$-62.21M | -$-72.06M | -$-76.37M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $436.3M | -$-116.84M | -$-336.35M | $169.4M | -$-273.3M |
| Common stock issued | $250M | $303M | $147.5M | $259.4M | $246.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-305.19M | $294.2M | $172.1M | $425.8M | $1.25B |
| Net change in cash | $690.2M | $153.8M | -$-53.67M | $46.4M | $323.1M |
| Cash at end of period | $1.66B | $968.7M | $814.9M | $868.6M | $822.2M |
| Operating cash flow | $524.1M | -$-8.31M | $104.2M | -$-541.27M | -$-641.69M |
| Capital expenditure | -$-58.7M | -$-34.28M | -$-62.21M | -$-72.06M | -$-76.37M |
| Free cash flow | $465.4M | -$-42.59M | $42M | -$-613.33M | -$-718.07M |
Line items
Line items
Line items
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
- CEO
- Yvonne L. Greenstreet
- Employees
- 2.5K
- Beta
- 0.27
Explore
Frequently asked questions
What is the intrinsic value of Alnylam Pharmaceuticals, Inc. (ALNY)?
Alnylam Pharmaceuticals, Inc. (ALNY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ALNY undervalued?
ALNY trades at a price of $143.82 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.